Budesonide Nasal Irrigation Versus Fluticasone Propionate Nasal Spray in Treating Allergic Rhinitis Patients

Budesonide Nasal Irrigation Versus Fluticasone Propionate Nasal Spray in the Treatment of Adult Patients With Allergic Rhinitis

NCT06858423•Benha University

View on ClinicalTrials.gov

Summary

Budesonide is a medication of the corticosteroid type. Available as an inhaler, nebulization solution, The inhaled form is used in the long-term management of asthma and chronic obstructive pulmonary disease is used for allergic rhinitis and nasal polyps fluticasone propionate

Detailed Description

The current study aims to compare between results of budesonid nasal irrigation and fluticasone nasal spray in the treatment of adult patients with Allergic Rhinitis.

Eligibility

Age

18 - 60 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Adult age between 18 and 60 years old.
•Patients with allergic rhinitis evidence by past skin prick testing. Patients were given a skin prick test with a panel of dog, cat, Dermatophagoides farinae, D pteronyssinus, Alternaria, Penicillium, Hormodendron, Aspergillus, grass pollen mix, tree pollen mix, and ragweed allergen extracts (100,000 Allergen Unit/mL). Histamine, 10 mg/mL, was used as a positive control, and the diluent was used as the negative control. A positive reaction was defined as a wheal diameter at least 3 mm greater than the diluent control and/or at least a 50-mm flare (ie, erythema measured as the sum of the greatest diameter and the perpendicular diameter through the midpoint of the greatest diameter)

Exclusion Criteria

•Patients who had autoimmune diseases or any immune compromised diseases including diabetes, chemotherapy.
•Patients with a history of nasal surgery.
•Patients who received systemic or topical corticosteroids, herbal drugs, beta blocking agent within the previous month of enrolment.
•Patients with asthma and COPD, nasal bleeding, obstructing nasal polyps, paranasal sinus.

Locations (1)

Benha University Hospitals - Otolaryngology department

Banhā, Qalyobia, Egypt

Key Dates

Start Date

August 15, 2023

Primary Completion Date

March 31, 2024

Completion Date

May 31, 2024

Last Updated

March 5, 2025

Enrollment

360

ACTUAL participants

Conditions

Nasal Allergy

Interventions

Budesonide buffered with 0.9% isotonic saline.

DRUG

Fluticasone propionate nasal spray.

DRUG

0.9% saline for nasal irrigation.

OTHER

TransMEM Gas Exchange -- Project 1, Aim 2

NCT01925729

Middle Ear DiseaseNasal Allergy

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 5, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions